Reassessing the role of GLP-1 receptor agonists in colorectal cancer Care.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in type 2 diabetes, yet their management after colorectal cancer diagnosis remains uncertain. A recent population-based cohort study reported lower mortality and fewer metastatic events among GLP-1 RA users than among patients receiving other glucose-lowering therapies. However, causal inference is limited by potential immortal time bias from the exposure definition, incomplete reporting of key prognostic and treatment factors (stage, surgery, systemic therapy, performance status), and unclear cohort entry and follow-up windows. In addition, reliance on routine administrative codes may misclassify outcomes. Time-varying exposure models, active-comparator new-user or landmark designs, and registry linkage/validation would strengthen the evidence.